Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H10O3 |
Molecular Weight | 214.2167 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(C=CC=C1)C(=O)OC2=CC=CC=C2
InChI
InChIKey=ZQBAKBUEJOMQEX-UHFFFAOYSA-N
InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23387858
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/23387858
Phenyl salicylate belongs to the family of hydroxybenzoic acid derivatives. Phenyl salicylate is used as a food additive. Antimycobacterial activity of phenyl salicylates (salols) was studied in connection with antituberculotic activity of salicylic derivatives. Phenyl salicylates are esters. Phenyl salicylates (salols) represent a new group of antimycobacterial compounds. Phenyl salicylate is included in the number of medications, indicated for the treatment of symptoms of irritative voiding, used to relieve the discomfort, pain, frequent urge to urinate, and cramps/spasms of the urinary tract caused by an infection or a medical procedure. Phenyl salicylate works as a pain reliever in these combinations.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22197706 |
49.78 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROSED EC Approved UsePROSED EC is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde. |
PubMed
Title | Date | PubMed |
---|---|---|
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay. | 2001 Feb |
|
Effect of some ultraviolet light absorbers on photo-stabilization of azadirachtin-A. | 2002 Oct |
|
Synthesis and V-ATPase inhibition of simplified lobatamide analogues. | 2002 Sep 5 |
|
Effect of ultraviolet light absorbers on photostabilization of azadirachtin-A in solution (part: II). | 2003 Jan |
|
Lobatamide C: total synthesis, stereochemical assignment, preparation of simplified analogues, and V-ATPase inhibition studies. | 2003 Jul 2 |
|
Viscosity at the dynamic crossover in o-terphenyl and salol under high pressure. | 2004 Jun 18 |
|
Interfacial effects on vitrification of confined glass-forming liquids. | 2005 Nov 15 |
|
Oxidation of anthracyclines by peroxidase metabolites of salicylic Acid. | 2005 Oct |
|
Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems. | 2006 Jan |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Depolarized light scattering versus optical Kerr effect spectroscopy of supercooled liquids: comparative analysis. | 2006 Sep 21 |
|
Fragrance material review on phenyl salicylate. | 2007 |
|
Investigating protein haptenation mechanisms of skin sensitisers using human serum albumin as a model protein. | 2007 Jun |
|
Degradation kinetics of hydrolytically susceptible drugs in O/W emulsions--effects of interfacial area and lecithin. | 2007 Sep 5 |
|
Mass spectrometric identification of covalent adducts of the skin allergen 2,4-dinitro-1-chlorobenzene and model skin proteins. | 2008 Aug |
|
The temperature dependence of free volume in phenyl salicylate and its relation to structural dynamics: a positron annihilation lifetime and pressure-volume-temperature study. | 2009 Apr 14 |
|
A direct test of the correlation between elastic parameters and fragility of ten glass formers and their relationship to elastic models of the glass transition. | 2009 Feb 14 |
|
Kinetic evidence for the occurrence of independent ion-exchange processes in the cationic micellar-mediated reaction of piperidine with anionic phenyl salicylate. | 2009 Jun 11 |
|
The role of nucleation in vitrification of supercooled liquids. | 2010 Apr 21 |
|
Determination of an ion exchange constant by the use of a kinetic probe: a new semiempirical kinetic approach involving the effects of 3-F- and 4-F-substituted benzoates on the rate of piperidinolysis of anionic phenyl salicylate in aqueous cationic micelles. | 2010 Jul 6 |
|
Infrared spectroscopy study of structural changes in glass-forming salol. | 2010 Mar |
|
Phenyl 3,5-di-tert-butyl-2-hy-droxy-benzoate. | 2010 Nov 24 |
|
A new semi-empirical kinetic method for the determination of ion exchange constants for the counterions of cationic micelles. | 2010 Sep 15 |
|
The estrogenic potential of salicylate esters and their possible risks in foods and cosmetics. | 2012 Mar 7 |
|
Simultaneous determination of the UV-filters benzyl salicylate, phenyl salicylate, octyl salicylate, homosalate, 3-(4-methylbenzylidene) camphor and 3-benzylidene camphor in human placental tissue by LC-MS/MS. Assessment of their in vitro endocrine activity. | 2013 Oct 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/drp/phenyl-salicylate.html
One tablet of PROSED EC orally 4 times per day followed by liberal fluid intake.
Each tablet of PROSED EC contains: Phenyl Salicylate 36.2 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24004914
Phenyl Salicylate at 10 uM increased the number of MCF-7 cells by approximately 1.8 fold
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
PHENYL SALICYLATE
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
||
|
WHO-VATC |
QG04BX12
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
||
|
WHO-ATC |
G04BX12
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
||
|
NCI_THESAURUS |
C2356
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C75079
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
DTXSID6021957
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
m8690
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
607
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
204-259-2
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
PHENYL SALICYLATE
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
1534209
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
28A37T47QO
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL1339216
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
895808
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
ALTERNATIVE | |||
|
C026041
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
34918
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
3462
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
SUB14839MIG
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
28A37T47QO
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
36122
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
DB11071
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
8361
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
118-55-8
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
100000079433
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY | |||
|
33406
Created by
admin on Fri Dec 15 16:45:01 GMT 2023 , Edited by admin on Fri Dec 15 16:45:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY